Losartan heart failure survival study: ELITE-II study end point summary
| Crude rate | Adjusted hazards ratio (95% CI) | p Value | |||||
|---|---|---|---|---|---|---|---|
| Captopril (n=1574) | Losartan (n=1578) | ||||||
| Primary end point | |||||||
| All cause mortality | 250 (15.9%) | 280 (17.7%) | 0.88 (0.75 to 1.05) | 0.16 | |||
| Secondary end point | |||||||
| Sudden death/resusc arrest | 115 (7.3%) | 142 (9.0%) | 0.80 (0.63 to 1.03) | 0.08 | |||
| Tertiary end points | |||||||
| All cause mortality/ hospitalisation | 707 (44.9%) | 752 (47.7%) | 0.94 (0.85 to 1.04) | 0.21 | |||
| Withdrawal for adverse experience | 228 (14.5%) | 149 (9.4%) | < 0.001 | ||||